SEC Form 4 · accession 0001209191-18-062349
Serina Therapeutics, Inc. · SER
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D West
Officer — Chief Executive Officer · Director
Period of report
Dec 10, 2018
Accepted (ET)
Dec 12, 2018 · 8:30 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001708599
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.0001 par valueF1 | Dec 10, 2018 | P | 4,000 | $3.8607 | A | 15,460 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price of $3.8607 per share represents a weighted average of prices ranging from $3.8566 to $3.8634 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.